Cargando…

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing world-wide in parallel to the increase of the obesity epidemic. Insulin resistance (IR) and the accumulation of triglyceride-derived toxic lipid metabolites play a key role in its patho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Filozof, Claudia, Goldstein, Barry J., Williams, Richard N., Sanyal, Arun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532706/ https://www.ncbi.nlm.nih.gov/pubmed/26201461 http://dx.doi.org/10.1007/s40265-015-0437-3

Ejemplares similares

Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic
por: Filozof, Claudia, et al.
Publicado: (2017)

Recent advances in understanding/management of non-alcoholic steatohepatitis
por: Pacana, Tommy, et al.
Publicado: (2015)

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program
por: Williams, RN, et al.
Publicado: (2016)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

LEARN algorithm: a novel option for predicting non-alcoholic steatohepatitis
por: Li, Gang, et al.
Publicado: (2023)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
por: Connelly, Margery A., et al.
Publicado: (2020)

Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
por: Sanyal, Arun J., et al.
Publicado: (2023)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Recent advances in understanding and managing non-alcoholic fatty liver disease
por: Albhaisi, Somaya, et al.
Publicado: (2018)

Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability
por: Almajed, Suaad, et al.
Publicado: (2021)

Assessing physician preferences on future therapeutic options and diagnostic practices in non-alcoholic steatohepatitis
por: Cook, Nigel, et al.
Publicado: (2020)

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
por: Luo, Yi, et al.
Publicado: (2021)

Limited applicability of cathepsin D for the diagnosis and monitoring of non‐alcoholic steatohepatitis
por: Kamarajah, Sivesh K, et al.
Publicado: (2019)

A new preclinical model of western diet‐induced progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma
por: Green, Christopher D., et al.
Publicado: (2022)

Hydrogels for the management of second-degree burns: currently available options and future promise
por: Cook, Katherine A, et al.
Publicado: (2022)

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
por: Dennis, Andrea, et al.
Publicado: (2021)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Combined alcoholic and non-alcoholic steatohepatitis
por: Ntandja Wandji, Line Carolle, et al.
Publicado: (2020)

Fibrosis-4 index is associated with the risk of hepatocellular carcinoma in patients with cirrhosis and nonalcoholic steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2023)

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
por: Doward, Lynda C., et al.
Publicado: (2020)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

Statins in Non-alcoholic Steatohepatitis
por: Torres-Peña, Jose D., et al.
Publicado: (2021)

Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
por: Baker, Susan S., et al.
Publicado: (2010)

Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma
por: Takakura, Kazuki, et al.
Publicado: (2019)

Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis
por: Kakehashi, Anna, et al.
Publicado: (2023)

Recent Least Burdensome Approach for the Approval of Innovative Medical Devices in Japan -Regulatory Approval Review of an Everolimus-eluting Bioresorbable Scaffold-
por: Konishi, Akihide, et al.
Publicado: (2020)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
por: Milic, Sandra, et al.
Publicado: (2015)

Biomedicines—Moving Biologic Agents into Approved Treatment Options
por: Cornetta, Kenneth
Publicado: (2013)

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
por: Sisay, Mekonnen
Publicado: (2020)

Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
por: Herring, Shawn, et al.
Publicado: (2021)

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia
por: Xiao, Jieling, et al.
Publicado: (2022)

The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis
por: Dywicki, Janine, et al.
Publicado: (2021)

Requirements and Study Designs for U.S. Regulatory Approval of Influenza Home Tests
por: Yang, Tony, et al.
Publicado: (2022)

Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science
por: Brar, Gurmehr, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rndh6rv23o5k161senlunh953r